Stock comparison
Alkermes
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ALKS
Alkermes
Market cap
$6.13B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ALKS | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 77B | LMAT |
| Benjamin Graham | 74D | 89A | LMAT |
| Philip Fisher | 58C | 81C | LMAT |
| Peter Lynch | 44D | 67B | LMAT |
| Joel Greenblatt | 51D | 56D | LMAT |
| Charlie Munger | 62D | 68D | LMAT |
| Terry Smith | 60D | 69D | LMAT |
Side-by-side metrics
| Metric | ALKS | LMAT |
|---|---|---|
| Market cap | $6.13B | $2.23B |
| P/E (TTM) | 41.7x | 37.1x |
| EV/EBIT | 30.0x | 36.6x |
| ROIC (TTM) | 3.89% | 9.43% |
| Gross margin | 86.63% | 72.39% |
| Net margin | 9.78% | 24.35% |
| Revenue CAGR 5y | 5.89% | 12.75% |
| EPS CAGR 5y | - | 19.04% |
| Debt / Equity | 0.9x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ALKS leads on
- Market cap$6.13Bvs $2.23B+64%
- EV/EBIT30.0xvs 36.6x+18%
- Gross margin86.63%vs 72.39%+16%
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- Net margin24.35%vs 9.78%+60%
- ROIC (TTM)9.43%vs 3.89%+59%
- Revenue CAGR 5y12.75%vs 5.89%+54%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.